biovie inc - BIVI

BIVI

Close Chg Chg %
1.72 -0.12 -6.98%

Closed Market

1.60

-0.12 (6.98%)

Volume: 143.16K

Last Updated:

Jun 5, 2026, 4:00 PM EDT

Company Overview: biovie inc - BIVI

BIVI Key Data

Open

$1.66

Day Range

1.56 - 1.77

52 Week Range

1.06 - 12.10

Market Cap

$12.97M

Shares Outstanding

7.54M

Public Float

7.18M

Beta

0.67

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$4.27

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

116.85K

 

BIVI Performance

1 Week
 
12.68%
 
1 Month
 
8.84%
 
3 Months
 
17.65%
 
1 Year
 
-85.19%
 
5 Years
 
-99.89%
 

BIVI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About biovie inc - BIVI

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

BIVI At a Glance

BioVie, Inc.
680 West Nye Lane
Carson City, Nevada 89703
Phone 1-775-888-3162 Revenue 0.00
Industry Biotechnology Net Income -17,542,120.00
Sector Health Technology Employees 13
Fiscal Year-end 06 / 2026
View SEC Filings

BIVI Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 0.931
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.198
Enterprise Value to Sales N/A
Total Debt to Enterprise Value -0.099

BIVI Efficiency

Revenue/Employee N/A
Income Per Employee -1,349,393.846
Receivables Turnover N/A
Total Asset Turnover N/A

BIVI Liquidity

Current Ratio 9.099
Quick Ratio 9.099
Cash Ratio 7.713

BIVI Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -75.014
Return on Equity -101.64
Return on Total Capital -90.601
Return on Invested Capital -99.831

BIVI Capital Structure

Total Debt to Total Equity 1.84
Total Debt to Total Capital 1.807
Total Debt to Total Assets 1.623
Long-Term Debt to Equity 1.449
Long-Term Debt to Total Capital 1.423
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Biovie Inc - BIVI

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
237.42K 266.84K 229.38K 229.38K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
237.42K 266.84K 229.38K 229.38K
Depreciation
- - 8.04K 37.47K
-
Amortization of Intangibles
229.38K 229.38K 229.38K 229.38K
COGS Growth
- +3.51% +12.39% -14.04%
Gross Income
(237.42K) (266.84K) (229.38K) (229.38K)
Gross Income Growth
- -3.51% -12.39% +14.04%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
27.02M 44.81M 31.96M 17.84M
Research & Development
17.26M 33.30M 23.10M 9.27M
Other SG&A
9.76M 11.51M 8.86M 8.57M
SGA Growth
-80.40% +65.88% -28.69% -44.18%
Other Operating Expense
- - - -
-
Unusual Expense
(3.29M) 1.44M (1.82M) (3.77K)
EBIT after Unusual Expense
(23.97M) (46.52M) (30.36M) (18.06M)
Non Operating Income/Expense
44.08K 562.26K 1.14M 853.03K
Non-Operating Interest Income
44.08K 562.26K 1.14M 853.03K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.16M 4.30M 2.89M 332.72K
Interest Expense Growth
+286.62% +98.81% -32.70% -88.50%
Gross Interest Expense
2.16M 4.30M 2.89M 332.72K
Interest Capitalized
- - - -
-
Pretax Income
(26.08M) (50.26M) (32.12M) (17.54M)
Pretax Income Growth
+79.97% -92.67% +36.09% +45.39%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(26.08M) (50.26M) (32.12M) (17.54M)
Minority Interest Expense
- - - -
-
Net Income
(26.08M) (50.26M) (32.12M) (17.54M)
Net Income Growth
+79.97% -92.67% +36.09% +45.39%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(26.08M) (50.26M) (32.12M) (17.54M)
Preferred Dividends
- - 886.42K 369.46K
-
Net Income Available to Common
(26.08M) (50.26M) (33.01M) (17.91M)
EPS (Basic)
-105.765 -154.712 -73.048 -12.124
EPS (Basic) Growth
+92.86% -46.28% +52.78% +83.40%
Basic Shares Outstanding
246.63K 324.83K 451.85K 1.48M
EPS (Diluted)
-105.765 -154.712 -73.048 -12.124
EPS (Diluted) Growth
+92.86% -46.28% +52.78% +83.40%
Diluted Shares Outstanding
246.63K 324.83K 451.85K 1.48M
EBITDA
(27.02M) (44.81M) (31.96M) (17.84M)
EBITDA Growth
+80.40% -65.88% +28.69% +44.18%
EBITDA Margin
- - - -
-

Biovie Inc in the News